Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 19/20 | 0.60 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503882 | 0.97 | MAP3K8 (0.62) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6510176 | 0.93 | MAP3K8 (0.65) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6507853 | 0.88 | MAP3K8 (0.62) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6529656 | 0.87 | MAP3K8 (0.64) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6503715 | 0.87 | MAP3K8 (0.66) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6504344 | 0.86 | MAP3K8 (0.68) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6502853 | 0.85 | MAP3K8 (0.67) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6502249 | 0.85 | MAP3K8 (0.58) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6505466 | 0.85 | MAP3K8 (0.69) | MAP3K8CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6508059 | 0.84 | MAP3K8 (0.64) | MAP3K8CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | MAP3K8 143/4885CDK1 4/4885CCNB1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.